// App-Quantinova.ai

OP0225 : TOFACITINIB AS MONOTHERAPY FOLLOWING METHOTREXATE WITHDRAWAL IN PATIENTS WITH PSORIATIC ARTHRITIS PREVIOUSLY TREATED WITH OPEN-LABEL TOFACITINIB + METHOTREXATE: A RANDOMISED, PLACEBO-CONTROLLED SUBSTUDY OF OPAL BALANCE

Researchers

Presenter

  • P. Nash

Principal Investigators

  • L. C. Coates

  • P. J. Mease

  • A. Kivitz

  • D. D. Gladman

  • F. Behrens

  • J. C. C. Wei

  • D. Fleishaker

  • J. Wu

  • C. Wang

  • A. B. Romero

  • L. Fallon

  • M. A. Hsu

  • K. Kanik

Medical Centers

  • Griffith University, Nathan, Australia.

  • University of Oxford, Oxford, United Kingdom

  • Altoona Center for Clinical Research, Duncansville, PA

  • Goethe University, Frankfurt, Germany

  • China Medical University Children's Hospital, Hematology and Oncology, Taichung, Taiwan, Republic of China

  • Pfizer, Inc, Groton, CT, United States of America

  • Pfizer Inc, Barcelona, Spain

  • Pfizer Canada, Montreal, QC, Canada

Locations

  • Australia

  • United Kingdom

  • United States

  • Canada

  • Germany

  • Republic of South Korea

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • NA

Study Id's

  • NCT01976364

  • NCT01877668

  • NCT01882439

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved